nodes	percent_of_prediction	percent_of_DWPC	metapath
Erythromycin—CYP3A4—bone cancer	0.423	1	CbGaD
Erythromycin—ABCC1—Epirubicin—bone cancer	0.115	0.232	CbGbCtD
Erythromycin—SLC22A7—Methotrexate—bone cancer	0.0755	0.152	CbGbCtD
Erythromycin—ABCC1—Doxorubicin—bone cancer	0.0612	0.123	CbGbCtD
Erythromycin—ABCC1—Methotrexate—bone cancer	0.0593	0.12	CbGbCtD
Erythromycin—SLCO1A2—Methotrexate—bone cancer	0.0529	0.107	CbGbCtD
Erythromycin—CYP2B6—Cisplatin—bone cancer	0.043	0.0867	CbGbCtD
Erythromycin—CYP2B6—Doxorubicin—bone cancer	0.0288	0.0581	CbGbCtD
Erythromycin—ABCB1—Cisplatin—bone cancer	0.022	0.0444	CbGbCtD
Erythromycin—ABCB1—Doxorubicin—bone cancer	0.0148	0.0298	CbGbCtD
Erythromycin—ABCB1—Methotrexate—bone cancer	0.0143	0.0289	CbGbCtD
Erythromycin—CYP3A4—Doxorubicin—bone cancer	0.00885	0.0178	CbGbCtD
Erythromycin—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00201	0.0434	CbGpPWpGaD
Erythromycin—Josamycin—CYP3A4—bone cancer	0.00167	0.292	CrCbGaD
Erythromycin—CYP3A7—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00152	0.0327	CbGpPWpGaD
Erythromycin—MLNR—G alpha (q) signalling events—GRM1—bone cancer	0.00125	0.0269	CbGpPWpGaD
Erythromycin—CYP2B6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00112	0.0242	CbGpPWpGaD
Erythromycin—ABCC1—Irinotecan Pathway—CYP3A4—bone cancer	0.00112	0.0241	CbGpPWpGaD
Erythromycin—MLNR—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.00112	0.0241	CbGpPWpGaD
Erythromycin—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0011	0.0237	CbGpPWpGaD
Erythromycin—SLC22A7—Fluoropyrimidine Activity—DHFR—bone cancer	0.000989	0.0213	CbGpPWpGaD
Erythromycin—CYP2B6—Liver X Receptor Pathway—CYP3A4—bone cancer	0.000943	0.0203	CbGpPWpGaD
Erythromycin—Sensitisation—Epirubicin—bone cancer	0.000904	0.0312	CcSEcCtD
Erythromycin—Azithromycin—CYP3A4—bone cancer	0.000903	0.157	CrCbGaD
Erythromycin—Roxithromycin—CYP3A4—bone cancer	0.000903	0.157	CrCbGaD
Erythromycin—ABCC1—Sphingosine 1-phosphate (S1P) pathway—GNA11—bone cancer	0.000891	0.0192	CbGpPWpGaD
Erythromycin—Telithromycin—CYP3A4—bone cancer	0.000878	0.153	CrCbGaD
Erythromycin—Sensitisation—Doxorubicin—bone cancer	0.000836	0.0289	CcSEcCtD
Erythromycin—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000832	0.0179	CbGpPWpGaD
Erythromycin—Hepatotoxicity—Cisplatin—bone cancer	0.000814	0.0281	CcSEcCtD
Erythromycin—MLNR—G alpha (q) signalling events—GNA11—bone cancer	0.000804	0.0173	CbGpPWpGaD
Erythromycin—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000779	0.0168	CbGpPWpGaD
Erythromycin—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000777	0.0168	CbGpPWpGaD
Erythromycin—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.000739	0.0159	CbGpPWpGaD
Erythromycin—CYP3A7—Xenobiotics—CYP3A4—bone cancer	0.000732	0.0158	CbGpPWpGaD
Erythromycin—MLNR—GPCR ligand binding—GRM4—bone cancer	0.000726	0.0156	CbGpPWpGaD
Erythromycin—Tenderness—Cisplatin—bone cancer	0.000721	0.0249	CcSEcCtD
Erythromycin—MLNR—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000719	0.0155	CbGpPWpGaD
Erythromycin—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000704	0.0152	CbGpPWpGaD
Erythromycin—Troleandomycin—CYP3A4—bone cancer	0.000694	0.121	CrCbGaD
Erythromycin—Clarithromycin—CYP3A4—bone cancer	0.000684	0.119	CrCbGaD
Erythromycin—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000661	0.0143	CbGpPWpGaD
Erythromycin—Hearing impaired—Cisplatin—bone cancer	0.000661	0.0228	CcSEcCtD
Erythromycin—Pain—Carboplatin—bone cancer	0.000654	0.0226	CcSEcCtD
Erythromycin—CYP3A7—Metapathway biotransformation—CYP4V2—bone cancer	0.000653	0.0141	CbGpPWpGaD
Erythromycin—MLNR—GPCR ligand binding—GRM1—bone cancer	0.000629	0.0136	CbGpPWpGaD
Erythromycin—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000607	0.0131	CbGpPWpGaD
Erythromycin—Skin exfoliation—Cisplatin—bone cancer	0.0006	0.0207	CcSEcCtD
Erythromycin—Eruption—Methotrexate—bone cancer	0.000561	0.0194	CcSEcCtD
Erythromycin—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000552	0.0119	CbGpPWpGaD
Erythromycin—CYP2B6—Xenobiotics—CYP3A4—bone cancer	0.000542	0.0117	CbGpPWpGaD
Erythromycin—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000529	0.0114	CbGpPWpGaD
Erythromycin—Eruption—Epirubicin—bone cancer	0.000525	0.0181	CcSEcCtD
Erythromycin—Deafness—Cisplatin—bone cancer	0.00051	0.0176	CcSEcCtD
Erythromycin—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00051	0.011	CbGpPWpGaD
Erythromycin—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000509	0.011	CbGpPWpGaD
Erythromycin—Burning sensation—Methotrexate—bone cancer	0.000497	0.0172	CcSEcCtD
Erythromycin—Eruption—Doxorubicin—bone cancer	0.000486	0.0168	CcSEcCtD
Erythromycin—CYP2B6—Metapathway biotransformation—CYP4V2—bone cancer	0.000483	0.0104	CbGpPWpGaD
Erythromycin—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00048	0.0103	CbGpPWpGaD
Erythromycin—Redness—Epirubicin—bone cancer	0.000478	0.0165	CcSEcCtD
Erythromycin—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000472	0.0102	CbGpPWpGaD
Erythromycin—Burning sensation—Epirubicin—bone cancer	0.000465	0.0161	CcSEcCtD
Erythromycin—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000455	0.00981	CbGpPWpGaD
Erythromycin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000447	0.00965	CbGpPWpGaD
Erythromycin—Hepatotoxicity—Methotrexate—bone cancer	0.000447	0.0154	CcSEcCtD
Erythromycin—MLNR—GPCR ligand binding—SMO—bone cancer	0.000443	0.00956	CbGpPWpGaD
Erythromycin—Redness—Doxorubicin—bone cancer	0.000443	0.0153	CcSEcCtD
Erythromycin—Ventricular arrhythmia—Epirubicin—bone cancer	0.000436	0.0151	CcSEcCtD
Erythromycin—Irritability—Cisplatin—bone cancer	0.000436	0.0151	CcSEcCtD
Erythromycin—Burning sensation—Doxorubicin—bone cancer	0.00043	0.0149	CcSEcCtD
Erythromycin—MLNR—GPCR downstream signaling—RGS1—bone cancer	0.00041	0.00884	CbGpPWpGaD
Erythromycin—MLNR—GPCR downstream signaling—GRM4—bone cancer	0.00041	0.00884	CbGpPWpGaD
Erythromycin—Ventricular arrhythmia—Doxorubicin—bone cancer	0.000404	0.0139	CcSEcCtD
Erythromycin—ABCC1—S1P1 pathway—PTGS2—bone cancer	0.000388	0.00836	CbGpPWpGaD
Erythromycin—Pancreatitis—Cisplatin—bone cancer	0.000387	0.0134	CcSEcCtD
Erythromycin—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000381	0.00822	CbGpPWpGaD
Erythromycin—Abdominal discomfort—Cisplatin—bone cancer	0.000378	0.0131	CcSEcCtD
Erythromycin—MLNR—Signaling by GPCR—GRM4—bone cancer	0.000372	0.00803	CbGpPWpGaD
Erythromycin—MLNR—Signaling by GPCR—RGS1—bone cancer	0.000372	0.00803	CbGpPWpGaD
Erythromycin—CYP2B6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000372	0.00802	CbGpPWpGaD
Erythromycin—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000364	0.00784	CbGpPWpGaD
Erythromycin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000357	0.0077	CbGpPWpGaD
Erythromycin—MLNR—GPCR downstream signaling—GRM1—bone cancer	0.000356	0.00767	CbGpPWpGaD
Erythromycin—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000354	0.00764	CbGpPWpGaD
Erythromycin—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000347	0.00748	CbGpPWpGaD
Erythromycin—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000332	0.00717	CbGpPWpGaD
Erythromycin—Skin exfoliation—Methotrexate—bone cancer	0.000329	0.0114	CcSEcCtD
Erythromycin—Ventricular tachycardia—Epirubicin—bone cancer	0.000323	0.0112	CcSEcCtD
Erythromycin—MLNR—Signaling by GPCR—GRM1—bone cancer	0.000323	0.00696	CbGpPWpGaD
Erythromycin—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000319	0.00688	CbGpPWpGaD
Erythromycin—Skin exfoliation—Epirubicin—bone cancer	0.000308	0.0107	CcSEcCtD
Erythromycin—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000307	0.00661	CbGpPWpGaD
Erythromycin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.000306	0.00659	CbGpPWpGaD
Erythromycin—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000304	0.00656	CbGpPWpGaD
Erythromycin—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.0003	0.00647	CbGpPWpGaD
Erythromycin—Ventricular tachycardia—Doxorubicin—bone cancer	0.000299	0.0103	CcSEcCtD
Erythromycin—Tinnitus—Cisplatin—bone cancer	0.000294	0.0102	CcSEcCtD
Erythromycin—Skin exfoliation—Doxorubicin—bone cancer	0.000285	0.00986	CcSEcCtD
Erythromycin—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000284	0.00613	CbGpPWpGaD
Erythromycin—Arrhythmia—Cisplatin—bone cancer	0.000282	0.00975	CcSEcCtD
Erythromycin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000276	0.00594	CbGpPWpGaD
Erythromycin—Erythema—Cisplatin—bone cancer	0.000275	0.0095	CcSEcCtD
Erythromycin—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000274	0.00592	CbGpPWpGaD
Erythromycin—Hepatic function abnormal—Epirubicin—bone cancer	0.000268	0.00927	CcSEcCtD
Erythromycin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000261	0.00564	CbGpPWpGaD
Erythromycin—Hepatic function abnormal—Doxorubicin—bone cancer	0.000248	0.00857	CcSEcCtD
Erythromycin—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000247	0.00532	CbGpPWpGaD
Erythromycin—Irritability—Methotrexate—bone cancer	0.000239	0.00826	CcSEcCtD
Erythromycin—Convulsion—Cisplatin—bone cancer	0.000238	0.00823	CcSEcCtD
Erythromycin—Liver function test abnormal—Methotrexate—bone cancer	0.000231	0.00799	CcSEcCtD
Erythromycin—Discomfort—Cisplatin—bone cancer	0.000231	0.00799	CcSEcCtD
Erythromycin—MLNR—GPCR downstream signaling—GNA11—bone cancer	0.000229	0.00494	CbGpPWpGaD
Erythromycin—MLNR—Signaling by GPCR—SMO—bone cancer	0.000227	0.00491	CbGpPWpGaD
Erythromycin—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000226	0.00779	CcSEcCtD
Erythromycin—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000225	0.00485	CbGpPWpGaD
Erythromycin—Anaphylactic shock—Cisplatin—bone cancer	0.000224	0.00775	CcSEcCtD
Erythromycin—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000222	0.00479	CbGpPWpGaD
Erythromycin—SLC22A7—Fluoropyrimidine Activity—TP53—bone cancer	0.000221	0.00476	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—GRM4—bone cancer	0.00022	0.00474	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—RGS1—bone cancer	0.00022	0.00474	CbGpPWpGaD
Erythromycin—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00022	0.00474	CbGpPWpGaD
Erythromycin—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.00022	0.00473	CbGpPWpGaD
Erythromycin—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000217	0.00468	CbGpPWpGaD
Erythromycin—Liver function test abnormal—Epirubicin—bone cancer	0.000216	0.00748	CcSEcCtD
Erythromycin—Anorexia—Cisplatin—bone cancer	0.000214	0.00739	CcSEcCtD
Erythromycin—Pancreatitis—Methotrexate—bone cancer	0.000212	0.00733	CcSEcCtD
Erythromycin—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000211	0.00729	CcSEcCtD
Erythromycin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000209	0.0045	CbGpPWpGaD
Erythromycin—MLNR—Signaling by GPCR—GNA11—bone cancer	0.000208	0.00449	CbGpPWpGaD
Erythromycin—MLNR—GPCR downstream signaling—IL3—bone cancer	0.000208	0.00448	CbGpPWpGaD
Erythromycin—Abdominal discomfort—Methotrexate—bone cancer	0.000208	0.00717	CcSEcCtD
Erythromycin—MLNR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000205	0.00441	CbGpPWpGaD
Erythromycin—Liver function test abnormal—Doxorubicin—bone cancer	0.0002	0.00692	CcSEcCtD
Erythromycin—Pancreatitis—Epirubicin—bone cancer	0.000199	0.00686	CcSEcCtD
Erythromycin—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000195	0.00675	CcSEcCtD
Erythromycin—Decreased appetite—Cisplatin—bone cancer	0.000195	0.00674	CcSEcCtD
Erythromycin—Pain—Cisplatin—bone cancer	0.000192	0.00663	CcSEcCtD
Erythromycin—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000191	0.00661	CcSEcCtD
Erythromycin—MLNR—Signaling Pathways—GRM1—bone cancer	0.000191	0.00411	CbGpPWpGaD
Erythromycin—MLNR—Signaling by GPCR—IL3—bone cancer	0.000189	0.00407	CbGpPWpGaD
Erythromycin—Feeling abnormal—Cisplatin—bone cancer	0.000185	0.00639	CcSEcCtD
Erythromycin—Pancreatitis—Doxorubicin—bone cancer	0.000184	0.00635	CcSEcCtD
Erythromycin—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000182	0.00393	CbGpPWpGaD
Erythromycin—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.00018	0.00388	CbGpPWpGaD
Erythromycin—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000179	0.00619	CcSEcCtD
Erythromycin—ABCC1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000179	0.00386	CbGpPWpGaD
Erythromycin—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000178	0.00384	CbGpPWpGaD
Erythromycin—Jaundice—Epirubicin—bone cancer	0.000176	0.00608	CcSEcCtD
Erythromycin—Hepatitis—Methotrexate—bone cancer	0.000173	0.00599	CcSEcCtD
Erythromycin—SLC22A7—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000171	0.0037	CbGpPWpGaD
Erythromycin—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000166	0.00573	CcSEcCtD
Erythromycin—Hypersensitivity—Cisplatin—bone cancer	0.000165	0.00571	CcSEcCtD
Erythromycin—Erythema multiforme—Methotrexate—bone cancer	0.000164	0.00566	CcSEcCtD
Erythromycin—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000164	0.00353	CbGpPWpGaD
Erythromycin—Jaundice—Doxorubicin—bone cancer	0.000163	0.00563	CcSEcCtD
Erythromycin—Hepatitis—Epirubicin—bone cancer	0.000162	0.0056	CcSEcCtD
Erythromycin—Tinnitus—Methotrexate—bone cancer	0.000162	0.00558	CcSEcCtD
Erythromycin—Diarrhoea—Cisplatin—bone cancer	0.000153	0.0053	CcSEcCtD
Erythromycin—Erythema multiforme—Epirubicin—bone cancer	0.000153	0.0053	CcSEcCtD
Erythromycin—Tinnitus—Epirubicin—bone cancer	0.000151	0.00522	CcSEcCtD
Erythromycin—Erythema—Methotrexate—bone cancer	0.000151	0.00521	CcSEcCtD
Erythromycin—Hepatitis—Doxorubicin—bone cancer	0.00015	0.00518	CcSEcCtD
Erythromycin—SLC22A7—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000148	0.00319	CbGpPWpGaD
Erythromycin—Dysgeusia—Methotrexate—bone cancer	0.000148	0.0051	CcSEcCtD
Erythromycin—Arrhythmia—Epirubicin—bone cancer	0.000145	0.005	CcSEcCtD
Erythromycin—Vomiting—Cisplatin—bone cancer	0.000143	0.00493	CcSEcCtD
Erythromycin—Erythema multiforme—Doxorubicin—bone cancer	0.000142	0.0049	CcSEcCtD
Erythromycin—Rash—Cisplatin—bone cancer	0.000141	0.00489	CcSEcCtD
Erythromycin—Erythema—Epirubicin—bone cancer	0.000141	0.00488	CcSEcCtD
Erythromycin—Tinnitus—Doxorubicin—bone cancer	0.00014	0.00483	CcSEcCtD
Erythromycin—Dysgeusia—Epirubicin—bone cancer	0.000138	0.00478	CcSEcCtD
Erythromycin—Vertigo—Methotrexate—bone cancer	0.000136	0.00468	CcSEcCtD
Erythromycin—MLNR—Signaling Pathways—SMO—bone cancer	0.000134	0.0029	CbGpPWpGaD
Erythromycin—Arrhythmia—Doxorubicin—bone cancer	0.000134	0.00463	CcSEcCtD
Erythromycin—Nausea—Cisplatin—bone cancer	0.000133	0.0046	CcSEcCtD
Erythromycin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000132	0.00286	CbGpPWpGaD
Erythromycin—CYP3A7—Biological oxidations—CYP3A4—bone cancer	0.000131	0.00282	CbGpPWpGaD
Erythromycin—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000131	0.00282	CbGpPWpGaD
Erythromycin—Convulsion—Methotrexate—bone cancer	0.000131	0.00452	CcSEcCtD
Erythromycin—Erythema—Doxorubicin—bone cancer	0.000131	0.00451	CcSEcCtD
Erythromycin—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	0.000129	0.00279	CbGpPWpGaD
Erythromycin—Chest pain—Methotrexate—bone cancer	0.000128	0.00444	CcSEcCtD
Erythromycin—SLCO1A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000128	0.00276	CbGpPWpGaD
Erythromycin—Dysgeusia—Doxorubicin—bone cancer	0.000128	0.00442	CcSEcCtD
Erythromycin—Discomfort—Methotrexate—bone cancer	0.000127	0.00438	CcSEcCtD
Erythromycin—Vertigo—Epirubicin—bone cancer	0.000127	0.00438	CcSEcCtD
Erythromycin—Palpitations—Epirubicin—bone cancer	0.000125	0.00431	CcSEcCtD
Erythromycin—Confusional state—Methotrexate—bone cancer	0.000124	0.00429	CcSEcCtD
Erythromycin—Anaphylactic shock—Methotrexate—bone cancer	0.000123	0.00425	CcSEcCtD
Erythromycin—MLNR—Signaling Pathways—GNA11—bone cancer	0.000123	0.00265	CbGpPWpGaD
Erythromycin—Convulsion—Epirubicin—bone cancer	0.000122	0.00423	CcSEcCtD
Erythromycin—Chest pain—Epirubicin—bone cancer	0.00012	0.00415	CcSEcCtD
Erythromycin—Discomfort—Epirubicin—bone cancer	0.000119	0.0041	CcSEcCtD
Erythromycin—Vertigo—Doxorubicin—bone cancer	0.000117	0.00405	CcSEcCtD
Erythromycin—Anorexia—Methotrexate—bone cancer	0.000117	0.00405	CcSEcCtD
Erythromycin—Confusional state—Epirubicin—bone cancer	0.000116	0.00401	CcSEcCtD
Erythromycin—Palpitations—Doxorubicin—bone cancer	0.000115	0.00399	CcSEcCtD
Erythromycin—Anaphylactic shock—Epirubicin—bone cancer	0.000115	0.00398	CcSEcCtD
Erythromycin—ABCC1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000115	0.00248	CbGpPWpGaD
Erythromycin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	0.000115	0.00248	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—ATF1—bone cancer	0.000114	0.00246	CbGpPWpGaD
Erythromycin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000114	0.00246	CbGpPWpGaD
Erythromycin—Convulsion—Doxorubicin—bone cancer	0.000113	0.00391	CcSEcCtD
Erythromycin—CYP3A7—Biological oxidations—GSTP1—bone cancer	0.000112	0.00242	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—IL3—bone cancer	0.000111	0.0024	CbGpPWpGaD
Erythromycin—Chest pain—Doxorubicin—bone cancer	0.000111	0.00384	CcSEcCtD
Erythromycin—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	0.00011	0.00238	CbGpPWpGaD
Erythromycin—SLCO1A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00011	0.00238	CbGpPWpGaD
Erythromycin—Discomfort—Doxorubicin—bone cancer	0.00011	0.0038	CcSEcCtD
Erythromycin—Anorexia—Epirubicin—bone cancer	0.00011	0.00379	CcSEcCtD
Erythromycin—Confusional state—Doxorubicin—bone cancer	0.000107	0.00371	CcSEcCtD
Erythromycin—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000107	0.00232	CbGpPWpGaD
Erythromycin—Decreased appetite—Methotrexate—bone cancer	0.000107	0.0037	CcSEcCtD
Erythromycin—Anaphylactic shock—Doxorubicin—bone cancer	0.000107	0.00368	CcSEcCtD
Erythromycin—Pain—Methotrexate—bone cancer	0.000105	0.00364	CcSEcCtD
Erythromycin—Anorexia—Doxorubicin—bone cancer	0.000102	0.00351	CcSEcCtD
Erythromycin—Feeling abnormal—Methotrexate—bone cancer	0.000101	0.0035	CcSEcCtD
Erythromycin—Gastrointestinal pain—Methotrexate—bone cancer	0.000101	0.00348	CcSEcCtD
Erythromycin—Decreased appetite—Epirubicin—bone cancer	0.0001	0.00346	CcSEcCtD
Erythromycin—SLCO1A2—Metabolism—NDUFA12—bone cancer	0.0001	0.00216	CbGpPWpGaD
Erythromycin—ABCC1—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.94e-05	0.00214	CbGpPWpGaD
Erythromycin—Pain—Epirubicin—bone cancer	9.85e-05	0.0034	CcSEcCtD
Erythromycin—Urticaria—Methotrexate—bone cancer	9.78e-05	0.00338	CcSEcCtD
Erythromycin—Abdominal pain—Methotrexate—bone cancer	9.73e-05	0.00336	CcSEcCtD
Erythromycin—CYP2B6—Biological oxidations—CYP3A4—bone cancer	9.69e-05	0.00209	CbGpPWpGaD
Erythromycin—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	9.55e-05	0.00206	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—TGFBR2—bone cancer	9.53e-05	0.00206	CbGpPWpGaD
Erythromycin—Feeling abnormal—Epirubicin—bone cancer	9.49e-05	0.00328	CcSEcCtD
Erythromycin—CYP3A5—Biological oxidations—CYP3A4—bone cancer	9.47e-05	0.00204	CbGpPWpGaD
Erythromycin—Gastrointestinal pain—Epirubicin—bone cancer	9.42e-05	0.00325	CcSEcCtD
Erythromycin—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	9.34e-05	0.00201	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	9.32e-05	0.00201	CbGpPWpGaD
Erythromycin—Decreased appetite—Doxorubicin—bone cancer	9.27e-05	0.0032	CcSEcCtD
Erythromycin—Urticaria—Epirubicin—bone cancer	9.15e-05	0.00316	CcSEcCtD
Erythromycin—Pain—Doxorubicin—bone cancer	9.11e-05	0.00315	CcSEcCtD
Erythromycin—Abdominal pain—Epirubicin—bone cancer	9.11e-05	0.00315	CcSEcCtD
Erythromycin—Hypersensitivity—Methotrexate—bone cancer	9.07e-05	0.00313	CcSEcCtD
Erythromycin—ABCC1—Metabolism—NDUFA12—bone cancer	9e-05	0.00194	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—IGF1R—bone cancer	8.97e-05	0.00193	CbGpPWpGaD
Erythromycin—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	8.83e-05	0.0019	CbGpPWpGaD
Erythromycin—Feeling abnormal—Doxorubicin—bone cancer	8.78e-05	0.00303	CcSEcCtD
Erythromycin—Gastrointestinal pain—Doxorubicin—bone cancer	8.72e-05	0.00301	CcSEcCtD
Erythromycin—Pruritus—Methotrexate—bone cancer	8.71e-05	0.00301	CcSEcCtD
Erythromycin—Hypersensitivity—Epirubicin—bone cancer	8.49e-05	0.00293	CcSEcCtD
Erythromycin—Urticaria—Doxorubicin—bone cancer	8.47e-05	0.00293	CcSEcCtD
Erythromycin—Abdominal pain—Doxorubicin—bone cancer	8.43e-05	0.00291	CcSEcCtD
Erythromycin—Diarrhoea—Methotrexate—bone cancer	8.42e-05	0.00291	CcSEcCtD
Erythromycin—CYP1A2—Phase II conjugation—GSTP1—bone cancer	8.34e-05	0.0018	CbGpPWpGaD
Erythromycin—SLCO1A2—Metabolism—NT5C3A—bone cancer	8.29e-05	0.00179	CbGpPWpGaD
Erythromycin—CYP2B6—Biological oxidations—GSTP1—bone cancer	8.28e-05	0.00179	CbGpPWpGaD
Erythromycin—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	8.17e-05	0.00176	CbGpPWpGaD
Erythromycin—Pruritus—Epirubicin—bone cancer	8.15e-05	0.00282	CcSEcCtD
Erythromycin—Dizziness—Methotrexate—bone cancer	8.14e-05	0.00281	CcSEcCtD
Erythromycin—CYP3A5—Biological oxidations—GSTP1—bone cancer	8.1e-05	0.00175	CbGpPWpGaD
Erythromycin—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	7.99e-05	0.00172	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	7.92e-05	0.00171	CbGpPWpGaD
Erythromycin—Diarrhoea—Epirubicin—bone cancer	7.88e-05	0.00272	CcSEcCtD
Erythromycin—Hypersensitivity—Doxorubicin—bone cancer	7.85e-05	0.00271	CcSEcCtD
Erythromycin—CYP3A7—Metabolism—NDUFA12—bone cancer	7.85e-05	0.00169	CbGpPWpGaD
Erythromycin—Vomiting—Methotrexate—bone cancer	7.83e-05	0.0027	CcSEcCtD
Erythromycin—Rash—Methotrexate—bone cancer	7.76e-05	0.00268	CcSEcCtD
Erythromycin—Dizziness—Epirubicin—bone cancer	7.62e-05	0.00263	CcSEcCtD
Erythromycin—Pruritus—Doxorubicin—bone cancer	7.54e-05	0.00261	CcSEcCtD
Erythromycin—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	7.53e-05	0.00162	CbGpPWpGaD
Erythromycin—ABCC1—Metabolism—NT5C3A—bone cancer	7.46e-05	0.00161	CbGpPWpGaD
Erythromycin—Vomiting—Epirubicin—bone cancer	7.32e-05	0.00253	CcSEcCtD
Erythromycin—Nausea—Methotrexate—bone cancer	7.31e-05	0.00253	CcSEcCtD
Erythromycin—Diarrhoea—Doxorubicin—bone cancer	7.29e-05	0.00252	CcSEcCtD
Erythromycin—Rash—Epirubicin—bone cancer	7.26e-05	0.00251	CcSEcCtD
Erythromycin—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	7.26e-05	0.00157	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	7.21e-05	0.00156	CbGpPWpGaD
Erythromycin—Dizziness—Doxorubicin—bone cancer	7.05e-05	0.00244	CcSEcCtD
Erythromycin—Nausea—Epirubicin—bone cancer	6.84e-05	0.00236	CcSEcCtD
Erythromycin—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	6.79e-05	0.00146	CbGpPWpGaD
Erythromycin—Vomiting—Doxorubicin—bone cancer	6.78e-05	0.00234	CcSEcCtD
Erythromycin—Rash—Doxorubicin—bone cancer	6.72e-05	0.00232	CcSEcCtD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	6.57e-05	0.00142	CbGpPWpGaD
Erythromycin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	6.54e-05	0.00141	CbGpPWpGaD
Erythromycin—CYP3A7—Metabolism—NT5C3A—bone cancer	6.51e-05	0.0014	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—KIT—bone cancer	6.5e-05	0.0014	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	6.48e-05	0.0014	CbGpPWpGaD
Erythromycin—Nausea—Doxorubicin—bone cancer	6.33e-05	0.00219	CcSEcCtD
Erythromycin—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	6.14e-05	0.00132	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—BRAF—bone cancer	6.11e-05	0.00132	CbGpPWpGaD
Erythromycin—MLNR—Signaling by GPCR—EGFR—bone cancer	5.92e-05	0.00128	CbGpPWpGaD
Erythromycin—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	5.81e-05	0.00125	CbGpPWpGaD
Erythromycin—CYP2B6—Metabolism—NDUFA12—bone cancer	5.81e-05	0.00125	CbGpPWpGaD
Erythromycin—CYP1A2—Biological oxidations—CYP3A4—bone cancer	5.7e-05	0.00123	CbGpPWpGaD
Erythromycin—CYP3A5—Metabolism—NDUFA12—bone cancer	5.68e-05	0.00122	CbGpPWpGaD
Erythromycin—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	5.63e-05	0.00121	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	5.49e-05	0.00118	CbGpPWpGaD
Erythromycin—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	5.48e-05	0.00118	CbGpPWpGaD
Erythromycin—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	5.15e-05	0.00111	CbGpPWpGaD
Erythromycin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	5.15e-05	0.00111	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—MDM2—bone cancer	5.12e-05	0.0011	CbGpPWpGaD
Erythromycin—CYP1A2—Biological oxidations—GSTP1—bone cancer	4.88e-05	0.00105	CbGpPWpGaD
Erythromycin—CYP2B6—Metabolism—NT5C3A—bone cancer	4.81e-05	0.00104	CbGpPWpGaD
Erythromycin—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	4.81e-05	0.00104	CbGpPWpGaD
Erythromycin—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.73e-05	0.00102	CbGpPWpGaD
Erythromycin—CYP3A5—Metabolism—NT5C3A—bone cancer	4.7e-05	0.00101	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—JUN—bone cancer	4.45e-05	0.00096	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—MMP9—bone cancer	4.33e-05	0.000934	CbGpPWpGaD
Erythromycin—ABCB1—Metabolism—NDUFA12—bone cancer	4.28e-05	0.000923	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	4.07e-05	0.000878	CbGpPWpGaD
Erythromycin—ABCC1—Disease—ENO2—bone cancer	3.9e-05	0.000841	CbGpPWpGaD
Erythromycin—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.76e-05	0.000812	CbGpPWpGaD
Erythromycin—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.71e-05	0.000801	CbGpPWpGaD
Erythromycin—SLCO1A2—Metabolism—ENO2—bone cancer	3.63e-05	0.000783	CbGpPWpGaD
Erythromycin—ABCC1—Disease—DHFR—bone cancer	3.62e-05	0.00078	CbGpPWpGaD
Erythromycin—ABCB1—Metabolism—NT5C3A—bone cancer	3.55e-05	0.000765	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—EGFR—bone cancer	3.5e-05	0.000755	CbGpPWpGaD
Erythromycin—CYP1A2—Metabolism—NDUFA12—bone cancer	3.42e-05	0.000737	CbGpPWpGaD
Erythromycin—SLCO1A2—Metabolism—DHFR—bone cancer	3.37e-05	0.000726	CbGpPWpGaD
Erythromycin—ABCC1—Metabolism—ENO2—bone cancer	3.27e-05	0.000705	CbGpPWpGaD
Erythromycin—SLCO1A2—Metabolism—GNA11—bone cancer	3.15e-05	0.000679	CbGpPWpGaD
Erythromycin—ABCC1—Metabolism—DHFR—bone cancer	3.03e-05	0.000654	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	3.02e-05	0.000651	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—TP53—bone cancer	2.94e-05	0.000634	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.91e-05	0.000628	CbGpPWpGaD
Erythromycin—SLCO1A2—Metabolism—CYP3A4—bone cancer	2.85e-05	0.000615	CbGpPWpGaD
Erythromycin—CYP3A7—Metabolism—ENO2—bone cancer	2.85e-05	0.000614	CbGpPWpGaD
Erythromycin—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.84e-05	0.000612	CbGpPWpGaD
Erythromycin—CYP1A2—Metabolism—NT5C3A—bone cancer	2.83e-05	0.000611	CbGpPWpGaD
Erythromycin—ABCC1—Metabolism—GNA11—bone cancer	2.83e-05	0.000611	CbGpPWpGaD
Erythromycin—CYP3A7—Metabolism—DHFR—bone cancer	2.64e-05	0.00057	CbGpPWpGaD
Erythromycin—CYP3A4—Metabolism—NDUFA12—bone cancer	2.64e-05	0.000569	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.62e-05	0.000566	CbGpPWpGaD
Erythromycin—ABCC1—Disease—TGFBR2—bone cancer	2.62e-05	0.000566	CbGpPWpGaD
Erythromycin—ABCC1—Metabolism—CYP3A4—bone cancer	2.57e-05	0.000554	CbGpPWpGaD
Erythromycin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.56e-05	0.000551	CbGpPWpGaD
Erythromycin—CYP3A7—Metabolism—GNA11—bone cancer	2.47e-05	0.000533	CbGpPWpGaD
Erythromycin—SLCO1A2—Metabolism—GSTP1—bone cancer	2.44e-05	0.000526	CbGpPWpGaD
Erythromycin—CYP3A7—Metabolism—CYP3A4—bone cancer	2.24e-05	0.000483	CbGpPWpGaD
Erythromycin—ABCC1—Metabolism—GSTP1—bone cancer	2.2e-05	0.000474	CbGpPWpGaD
Erythromycin—CYP3A4—Metabolism—NT5C3A—bone cancer	2.19e-05	0.000471	CbGpPWpGaD
Erythromycin—CYP2B6—Metabolism—ENO2—bone cancer	2.11e-05	0.000454	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.06e-05	0.000445	CbGpPWpGaD
Erythromycin—CYP3A5—Metabolism—ENO2—bone cancer	2.06e-05	0.000444	CbGpPWpGaD
Erythromycin—CYP2B6—Metabolism—DHFR—bone cancer	1.96e-05	0.000422	CbGpPWpGaD
Erythromycin—CYP3A7—Metabolism—GSTP1—bone cancer	1.92e-05	0.000413	CbGpPWpGaD
Erythromycin—CYP3A5—Metabolism—DHFR—bone cancer	1.91e-05	0.000412	CbGpPWpGaD
Erythromycin—CYP2B6—Metabolism—GNA11—bone cancer	1.83e-05	0.000394	CbGpPWpGaD
Erythromycin—ABCC1—Disease—KIT—bone cancer	1.79e-05	0.000386	CbGpPWpGaD
Erythromycin—CYP3A5—Metabolism—GNA11—bone cancer	1.79e-05	0.000385	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.73e-05	0.000374	CbGpPWpGaD
Erythromycin—ABCC1—Disease—BRAF—bone cancer	1.68e-05	0.000363	CbGpPWpGaD
Erythromycin—CYP2B6—Metabolism—CYP3A4—bone cancer	1.66e-05	0.000357	CbGpPWpGaD
Erythromycin—CYP3A5—Metabolism—CYP3A4—bone cancer	1.62e-05	0.000349	CbGpPWpGaD
Erythromycin—ABCB1—Metabolism—ENO2—bone cancer	1.55e-05	0.000335	CbGpPWpGaD
Erythromycin—ABCB1—Metabolism—DHFR—bone cancer	1.44e-05	0.000311	CbGpPWpGaD
Erythromycin—CYP2B6—Metabolism—GSTP1—bone cancer	1.42e-05	0.000306	CbGpPWpGaD
Erythromycin—ABCC1—Disease—MDM2—bone cancer	1.41e-05	0.000304	CbGpPWpGaD
Erythromycin—CYP3A5—Metabolism—GSTP1—bone cancer	1.38e-05	0.000299	CbGpPWpGaD
Erythromycin—ABCC1—Disease—PTGS2—bone cancer	1.36e-05	0.000293	CbGpPWpGaD
Erythromycin—ABCB1—Metabolism—GNA11—bone cancer	1.35e-05	0.000291	CbGpPWpGaD
Erythromycin—SLCO1A2—Metabolism—PTGS2—bone cancer	1.26e-05	0.000273	CbGpPWpGaD
Erythromycin—CYP1A2—Metabolism—ENO2—bone cancer	1.24e-05	0.000268	CbGpPWpGaD
Erythromycin—ABCB1—Metabolism—CYP3A4—bone cancer	1.22e-05	0.000263	CbGpPWpGaD
Erythromycin—CYP1A2—Metabolism—DHFR—bone cancer	1.15e-05	0.000248	CbGpPWpGaD
Erythromycin—ABCC1—Metabolism—PTGS2—bone cancer	1.14e-05	0.000245	CbGpPWpGaD
Erythromycin—CYP1A2—Metabolism—GNA11—bone cancer	1.08e-05	0.000232	CbGpPWpGaD
Erythromycin—ABCB1—Metabolism—GSTP1—bone cancer	1.04e-05	0.000225	CbGpPWpGaD
Erythromycin—CYP3A7—Metabolism—PTGS2—bone cancer	9.92e-06	0.000214	CbGpPWpGaD
Erythromycin—CYP1A2—Metabolism—CYP3A4—bone cancer	9.75e-06	0.00021	CbGpPWpGaD
Erythromycin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.7e-06	0.000209	CbGpPWpGaD
Erythromycin—ABCC1—Disease—EGFR—bone cancer	9.63e-06	0.000208	CbGpPWpGaD
Erythromycin—CYP3A4—Metabolism—ENO2—bone cancer	9.58e-06	0.000207	CbGpPWpGaD
Erythromycin—CYP3A4—Metabolism—DHFR—bone cancer	8.88e-06	0.000192	CbGpPWpGaD
Erythromycin—CYP1A2—Metabolism—GSTP1—bone cancer	8.34e-06	0.00018	CbGpPWpGaD
Erythromycin—CYP3A4—Metabolism—GNA11—bone cancer	8.3e-06	0.000179	CbGpPWpGaD
Erythromycin—CYP2B6—Metabolism—PTGS2—bone cancer	7.34e-06	0.000158	CbGpPWpGaD
Erythromycin—CYP3A5—Metabolism—PTGS2—bone cancer	7.17e-06	0.000155	CbGpPWpGaD
Erythromycin—CYP3A4—Metabolism—GSTP1—bone cancer	6.44e-06	0.000139	CbGpPWpGaD
Erythromycin—ABCB1—Metabolism—PTGS2—bone cancer	5.41e-06	0.000117	CbGpPWpGaD
Erythromycin—CYP1A2—Metabolism—PTGS2—bone cancer	4.32e-06	9.32e-05	CbGpPWpGaD
Erythromycin—CYP3A4—Metabolism—PTGS2—bone cancer	3.34e-06	7.19e-05	CbGpPWpGaD
